



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

OIPE TRANSMITTAL FORM <small>(to be used for all correspondence after initial filing)</small>		Application Number 10/516,381
		Filing Date November 30, 2004
		First Named Inventor Guenther Eissner
		Art Unit
		Examiner Name
Total Number of Pages in This Submission 6		Attorney Docket Number 014442-000022

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (<i>Appeal Notice, Brief, Reply Brief</i>) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): One copy of each of the 38 cited references; acknowledgement postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	MOORE & VAN ALLEN	
Signature		
Printed Name	JENNIFER L. SKORD	
Date	April 26, 2005	Reg. No. 30,687

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Signature		
Typed or printed name	Katrina Holland	Date April 26, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#5

In re application of: Guenther Eissner

Group Art Unit: Not Yet Assigned

Serial Number: 10/516,381

Examiner: Not Yet Assigned

Filed: November 30, 2004

For: METHOD FOR THE PROTECTION OF ENDOTHELIAL AND EPITHCLIAL CELLS
DURING CHEMOTHERAPY

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND 37 C.F.R. § 1.97

It is respectfully requested that the documents listed on the attached Forms PTO/SB/08B be considered by the Patent and Trademark Office in the above-referenced application and made of record therein. Full text copies of the relevant documents are enclosed. This information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last.

Respectfully submitted,

By:

April 26, 2005

Date

Jennifer L. Skord
Registration No. 30,687
Attorney for Applicant
Moore & Van Allen, PLLC
430 Davis Dr., Suite 500
Morrisville, NC 27560-6832
Phone: 919-286-8000
Facsimile: 919-286-8199

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service as first class mail on April 25, 2005/April 26, 2005, in an envelope addressed to Commissioner of Patents, PO Box 1450, Alexandria, VA 22313-1450

Katrina Holland

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known		
Sheet	1	of	4	Attorney Docket Number
NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	K	WEISS, Mark A.; Novel Treatment Strategies in Chronic Lymphocytic Leukemia; Current Oncology Reports; 2001; 3:217-222; Current Science Inc., USA		
	L	HOLLER, E., et al.; Increased Serum Levels of Tumor Necrosis Factor α Precede Major Complications of Bone Marrow Transplantation; Blood; 1990; Vol 75, No. 4; pp. 1011-1016; The American Society of Hematology, USA		
	M	ANTIN, Joseph H., et al.; Cytokine Dysregulation and Acute Graft-Versus-Host Disease; Blood; 1992; Vol. 80, No. 12; pp. 2964-2968; The American Society of Hematology, USA		
	N	XUN, Chang Q., et al.; Effect of Total Body Irradiation, Busulfan-Cyclophosphamide, or Chclophosphamide Conditioning on Inflammatory Cytokine Release and Development of Acute and Chronic Graft-Versus-Host Disease in H-2-Incompatible Transplanted SCID Mice; Blood; 1994; Vol. 83, No. 8, pp. 2360-2367; The American Society of Hematology, USA		
	O	WEINER, Roy S., M.D., et al.; Interstitial Pneumonitis After Bone Marrow Transplantation; Annals of Internal Medicine; 1986; 104:168-175; American College of Physicians, USA		
	P	WÄSCH, R., et al.; Rapid Achievement of Complete Donor Chimerism and Low Regimen-Related Toxicity After Reduced Conditioning with Fludarabine, Carmustine, Melphalan and Allogeneic Transplantation; Bone Marrow Transplantation; 2000; 26:243-250; Macmillan Publishers Ltd., USA		
	Q	CARELLA, AM, et al.; Mini-Allografts: Ongoing Trials in Humans; Bone Marrow Transplantation; 2000; 25: 345-350; Macmillan Publishers Ltd., USA		
	R	SLAVIN, Shimon, et al.; Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation with Lethal Cytoablation for the Treatment of Malignant and Nonmalignant Hematologic Diseases; Blood; 1998; Vol. 91, Vol. 3; pp. 756-763; The American Society of Hematology, USA		
	S	HOLLER, E., et al.; Microangiopathy in Patients on Cyclosporine Prophylaxis Who Developed Acute Graft-Versus-Host Disease After HLA-Identical Bone Marrow Transplantation; Blood; 1989; Vol. 73, No. 7; pp. 2018-2024; Grune & Stratton, Inc.		
	T	EISSNER, Günther; et al.; Critical Involvement of Transmembrane Tumor Necrosis Factor- α in Endothelial Programmed Cell Death Mediated by Ionizing Radiation and Bacterial Endotoxin; Blood; 1995; Vol. 86, No. 11; pp. 4184-4193; The American Society of Hematology, USA		
Examiner Signature			Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p style="text-align: center;"><i>O I P</i></p> <p><i>APR 28 2005</i></p> <p>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/516,381
				Filing Date	November 30, 2004
				First Named Inventor	Guenther Eissner
				Art Unit	
				Examiner Name	
Sheet	2	of	4	Attorney Docket Number	014442-000022

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	U	LINDNER, Heidrun, et al.; Peripheral Blood Mononuclear Cells Induce Programmed Cell Death in Human Endothelial Cells and May Prevent Repair: Role of Cytokines; Blood; 1997; Vol. 89, No. 6; pp. 1931-1938; The American Society of Hematology, USA			
	V	HAIMOVITZ-FRIEDMAN, Adriana, et al.; Protein Kinase C Mediates Basic Fibroblast Growth Factor Protection of Endothelial Cells Against Radiation-Induced Apoptosis; Cancer Research; 1994; 54: 2591-2597; Department of Radiation Oncology, USA			
	W	FUKS, Zvi, et al.; Basic Fibroblast Growth Factor Protects Endothelial Cells Against Radiation-Induced Programmed Cell Death <i>in Vitro</i> and <i>in Vivo</i> ; Cancer Research; 1994; 54: 2582-2590; Department of Radiation Oncology, USA			
	X	EISSNER, Gunther, et al.; Influence of Bacterial Endotoxin on Radiation-Induced Activation of Human Endothelial Cells <i>in Vitro</i> and <i>in Vivo</i> ; Transplantation; 1996; Vol. 62, No. 6; pp. 819-827; Williams & Wilkins, USA			
	Y	LINDNER, Heidrun, et al.; Influence of Bacterial Endotoxin on Radiation-Induced Activation of Human Endothelial Cells <i>in Vitro</i> and <i>in Vivo</i> ; Transplantation; 1997; Vol. 64, No. 9; pp. 1370-1373; Williams & Wilkins, USA			
	Z	BEELEN, Dietrich W., et al.; Evidence that Sustained Growth Suppression of Intestinal Anaerobic Bacteria Reduces the Risk of Acute Graft-Versus-Host Disease After Sibling Marrow Transplantation; Blood; 1992; Vol. 80, No. 10; pp. 2668-2676; The American Society of Hematology, USA			
	AA	EISSNER, G., et al.; Influence of Bacterial Endotoxin on the Allogenicity of Human Endothelial Cells; Correspondence; pp. 1286-1288			
	AB	ADES, Edwin W., et al.; HMEC-1: Establishment of an immortalized Human Microvascular Endothelial Cell Line; The Journal of Investigative Dermatology; 1992; Vol. 99, No. 6; pp. 683-690; The Society for Investigative Dermatology, Inc., USA			
	AC	COTTER, Thomas G., et al.; Microfilament-disrupting Agents Prevent the Formation of Apoptotic Bodies in Tumor Cells Undergoing Apoptosis; Cancer Research; 1992; 52: 997-1005; Department of Biology, St. Patrick's College, Ireland			
	AD	LEE, Alison, et al.; Inhibition of Apoptosis and Prolongation of Neutrophil Functional Longevity by Inflammatory Mediators; Journal of Leukocyte Biology; 1993; Vol. 54, pp. 283-288; Department of Respiratory Medicine, University of Edinburgh, United Kingdom			

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	10/516,381
				Filing Date	November 30, 2004
				First Named Inventor	Guenther Eissner
				Art Unit	
				Examiner Name	
(use as many sheets as necessary)					
Sheet	3	of	4	Attorney Docket Number	014442-000022

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	AE	WESTPHAL, J.R., et al.; Accessory Function of Endothelial Cells in Anti-CD3-Induced T-Cell Proliferation: Synergism with Monocytes; Scand. J. Immunol.; 1992; 35:449-457; Institute of Pathology and Department of Medicine, Division of Nephrology, University Hospital Nijmegen, The Netherlands			
	AF	MACDONALD, H. Robson, et al.; Generation of Cytotoxic T Lymphocytes in Vitro; The Journal of Experimental Medicine; 1974; Vol. 140; pp. 718-730; Department of Immunology, Swiss Institute for Experimental Cancer Research, Switzerland			
	AG	LONG, Eric O.; Regulation of Immune Responses Through Inhibitory Receptors; Annu. Rev. Immunol.; 1999; 17:875-904; Annual Reviews, USA			
	AH	NAGLER, Arnon, et al.; Low-Intensity Conditioning is Sufficient to Ensure Engraftment in Matched Unrelated Bone Marrow Transplantation; Experimental Hematology; 2001; 29:362-370; Elsevier Science, Europe			
	AI	MICHALLET, Mauricette, et al.; Allogeneic Hematopoietic Stem-Cell Transplantation After Nonmyeloablative Preparative Regimens: Impact of Pretransplantation and Posttransplantation Factors on Outcome; Journal of Clinical Oncology; 2001; Vol. 19, No. 4; pp. 3340-3349; The American Society of Clinical Oncology, USA			
	AJ	HILDEBRANDT, G., et al.; Analysis of Pulmonary Function After Allogeneic Bone Marrow (BMT) or Blood Stem Cell Transplantation (PBSCT) Using Conditioning Regimens with Total Body Irradiation (TBI) and Conventional Intensity Compared to Regimens Without TBI with Reduced Intensity; p. 578			
	AK	BORNHÄUSER, M., et al.; Dose-Reduced Conditioning for Allogeneic Blood Stem Cell Transplantation: Durable Engraftment Without Antithymocyte Globulin; Bone Marrow Transplantation; 2000; 26: 119-125; Macmillan Publishers, USA			
	AL	GENINI, Davide, et al.; Nucleotide Requirements for the <i>in Vitro</i> Activation of the Apoptosis Protein-Activating Factor-1-Mediated Caspase Pathway; The Journal of Biological Chemistry; 2000; Vol. 275, No. 1; pp. 29-34; The American Society for Biochemistry and Molecular Biology, Inc., USA			
	AM	BIEDERMANN, Barbara C., et al.; Human Vascular Endothelial Cells Favor Clonal Expansion of Unusual Alloreactive CTL; The Journal of Immunology; 1999; pp. 7022-7030; The American Association of Immunologists, USA			
	AN	BRISCOE, David M., et al.; Interactions Between T Lymphocytes and Endothelial Cells in Allograft Rejection; Current Opinion in Immunology; 1998; 10:525-531; Current Biology Ltd., USA			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		APR 28 2005		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				
(use as many sheets as necessary)				
Sheet	4	of	4	Attorney Docket Number
014442-000022				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	AO	PEGRAM, Anita A., et al.; Prevention and Treatment of Veno-Occlusive Disease; The Annals of Pharmacotherapy; 2001; Vol. 35; pp. 935-942; USA		T ²
	AP	ROSSONI, Giuseppe, Ph.D., et al.; Protectant Activity of Defibrotide in Cardioplegia Followed by Ischemia/Reperfusion Injury in the Isolated Rat Heart; J. Card Surg; 1999; 14:334-341		
	AQ	ROSSONI, Giuseppe, et al.; Defibrotide Normalizes Cardiovascular Function Hampered by Established Atherosclerosis in the Rabbit; Thrombosis Research; 2000; 97:29-38; Elsevier Science Ltd., Europe		
	AR	POGLIANI, Enrico Maria, et al.; Defibrotide in Recurrent Thrombotic Thrombocytopenic Purpura; Clin Appl Thrombosis/Hemostasis; 2000; 6(2): 69-70; Lippincott Williams & Wilkins, Inc., USA		
	AS	SAN, Tangül, et al., Protective Effect of Defibrotide on Perfusion Induced Endothelial Damage; Thrombosis Research; 2000; 99:335-341; Elsevier Science Ltd., Europe		
	AT	CHOPRA, R., et al.; Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Results of the European Compassionate-Use Study; British journal of Haematology; 2000; 111: 1122-1129; Blackwell Science Ltd.		
	AU	FERRARA, James L.M., et al.; Pathophysiologic Mechanisms of Acute Graft-vs.-Host Disease; Biology of Blood and Marrow Transplantation; 1999; 5:347-356; American Society for Blood and Marrow Transplantation, USA		
	AV	HUANG, Peng, et al.; Gene Deletion, a Mechanism of Induced Mutation by Arabinosyl Nucleosides; Mutation Research; 1989; 210:291-301; ElsevierScience Publishers B.V. (Biomedical Division)		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.